Status:
RECRUITING
Comparison Between Treatments of Oligohydramnios
Lead Sponsor:
Kafrelsheikh University
Conditions:
Oligohydramnios
Eligibility:
FEMALE
18-35 years
Phase:
PHASE2
Brief Summary
Based on previous studies, Both sildenafil and L-arginine helped to improve idiopathic oligohydramnios. In this study, Level of improvment of oligohydramnios will be compared. As well as, NICU admiss...
Eligibility Criteria
Inclusion
- Pregnant women with gestational age between 26-37 weeks
- Pregnant women whose age is \< 35 years
- Woman with other indication for elective caesarean section.
- Women carrying a single fetus with no major anomalies.
- Initial amniotic fluid index \<8cm determined by reliable pelivabdominal ultrasound.
Exclusion
- Women complaining of other obstetric disorder such as, PPROM, preeclampsia, or diabetes.
- Women with chronic illness such as, chronic hypertension, autoimmune disease or kidney disease.
- Women who received other treatments for oligohydramnios in current pregnancy.
- Women who smoke.
- Fetuses with major congenital anomaly.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT07135037
Start Date
September 1 2024
End Date
December 31 2025
Last Update
August 21 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Kafrelsheikh University Hospital
Kafr ash Shaykh, Kafrelsheikh, Egypt, 33513
2
Kafrelsheokh university hospital
Kafr ash Shaykh, Kafrelsheikh, Egypt, 33513